BioCentury
ARTICLE | Finance

Genome toolbox

How Inscripta complements genome reading, writing plays in investors’ portfolios

March 2, 2018 9:12 PM UTC

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing.

New investor Mérieux Développement and existing investor Paladin Capital led the round, which closed on Feb. 28, joined by existing investors Venrock, Foresite, MLS Capital and NanoDimension. ...

BCIQ Company Profiles

Inscripta Inc.